NAU IB Capital (KOSDAQ:293580)
1,430.00
+12.00 (0.85%)
At close: Sep 8, 2026
NAU IB Capital Revenue
NAU IB Capital had revenue of 3.67B KRW in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 22.28B, up 54.62% year-over-year. In the year 2025, NAU IB Capital had annual revenue of 20.64B with 46.41% growth.
Revenue (ttm)
22.28B
Revenue Growth
+54.62%
P/S Ratio
6.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
133.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.64B | 6.54B | 46.41% |
| Dec 31, 2024 | 14.10B | -5.66B | -28.64% |
| Dec 31, 2023 | 19.76B | 5.83B | 41.86% |
| Dec 31, 2022 | 13.93B | -11.63B | -45.50% |
| Dec 31, 2021 | 25.56B | 15.71B | 159.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Gradiant | 3.43T |
| Maeil Holdings | 2.24T |
| Ubiquoss Holdings | 159.35B |
| Kencoa Aerospace | 95.62B |
| Innotech | 75.71B |
| HMNEX | 48.07B |
| REMEDI | 22.77B |
| TiumBio | 15.00B |